Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ander Mayor

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
The American Journal of Dermatopathology|August 21, 2014
Diffuse Reactive Angioendotheliomatosis Secondary to the Administration of Trabectedin and PegfilgrastimAnder Mayor-Ibarguren, Cristina Gómez-Fernández, María J Beato-Merino, et al.
International Journal of Dermatology|July 16, 2015
Herpes zoster: a potential risk associated with fingolimod treatmentAnder Mayor Ibarguren, Cristina Gómez Fernández, Antonio Tallón Barranco, et al.
Pediatric Dermatology|June 2, 2017
Mucositis Secondary to Chlamydia pneumoniae Infection: Expanding the Mycoplasma pneumoniae-Induced Rash and Mucositis ConceptAnder Mayor-Ibarguren, Marta Feito-Rodriguez, Jéssica González-Ramos, et al.
Journal of the American Academy of Dermatology|October 16, 2023
Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: A retrospective cohort from the European Task Force of Dermatology for Cancer patientsFrancesc Alamon-Reig, Xavier Bosch-Amate, Priscila Giavedoni, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 17, 2023
Subacute cutaneous lupus erythematosus following ribociclib therapy for metastatic breast cancerVictoria Lucia Collada Sánchez, Javier Álvarez Criado, Virginia Martinez Martin, et al.
Clinical Drug Investigation|July 4, 2023
Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and OptimisationPedro Herranz-Pinto, Maria Luisa Alonso-Pacheco, Rosa Feltes-Ochoa, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 28, 2026
Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody-drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and VenereologyMargarita Majem, Kevin Molina Mata, Ander Mayor Ibarguren, et al.
International Journal of Dermatology|October 18, 2020
High prevalence of cryofibrinogenemia in patients with chilblains during the COVID-19 outbreakCristina Gómez-Fernández, Ana E López-Sundh, Carmen González-Vela, et al.
BMJ Open|July 10, 2023
Identifying biomarkers of treatment response to ciclosporin in atopic dermatitis through multiomic predictive modelling: DERMATOMICS study protocolAlicia Marín-Candón, Irene García-García, Pedro Arias, et al.
Acta Dermato-Venereologica|May 21, 2026
Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case SeriesCecilia Tejero-García, Francesc Alamon Reig, Xavier Bosch-Amate, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
The American Journal of Dermatopathology|August 21, 2014
Diffuse Reactive Angioendotheliomatosis Secondary to the Administration of Trabectedin and PegfilgrastimAnder Mayor-Ibarguren, Cristina Gómez-Fernández, María J Beato-Merino, et al.
International Journal of Dermatology|July 16, 2015
Herpes zoster: a potential risk associated with fingolimod treatmentAnder Mayor Ibarguren, Cristina Gómez Fernández, Antonio Tallón Barranco, et al.
Pediatric Dermatology|June 2, 2017
Mucositis Secondary to Chlamydia pneumoniae Infection: Expanding the Mycoplasma pneumoniae-Induced Rash and Mucositis ConceptAnder Mayor-Ibarguren, Marta Feito-Rodriguez, Jéssica González-Ramos, et al.
Journal of the American Academy of Dermatology|October 16, 2023
Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: A retrospective cohort from the European Task Force of Dermatology for Cancer patientsFrancesc Alamon-Reig, Xavier Bosch-Amate, Priscila Giavedoni, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 17, 2023
Subacute cutaneous lupus erythematosus following ribociclib therapy for metastatic breast cancerVictoria Lucia Collada Sánchez, Javier Álvarez Criado, Virginia Martinez Martin, et al.
Clinical Drug Investigation|July 4, 2023
Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and OptimisationPedro Herranz-Pinto, Maria Luisa Alonso-Pacheco, Rosa Feltes-Ochoa, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 28, 2026
Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody-drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and VenereologyMargarita Majem, Kevin Molina Mata, Ander Mayor Ibarguren, et al.
International Journal of Dermatology|October 18, 2020
High prevalence of cryofibrinogenemia in patients with chilblains during the COVID-19 outbreakCristina Gómez-Fernández, Ana E López-Sundh, Carmen González-Vela, et al.
BMJ Open|July 10, 2023
Identifying biomarkers of treatment response to ciclosporin in atopic dermatitis through multiomic predictive modelling: DERMATOMICS study protocolAlicia Marín-Candón, Irene García-García, Pedro Arias, et al.
Acta Dermato-Venereologica|May 21, 2026
Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case SeriesCecilia Tejero-García, Francesc Alamon Reig, Xavier Bosch-Amate, et al.
Pageof 3